Herpes Simplex Virus (HSV) Diagnostics Market: By Type of Test (Viral Culture Test, Nucleic Acid Amplification Test (NAATs), and Anti-biotic Test), By Disease Type (HSV-I and HSV-II), By End-users (Hospital & Clinics, Research Institutions, and Diagnostic Laboratories), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Herpes Simplex Virus Diagnostics Market is expected to grow at a CAGR of 6.4% from 2024 to 2030, from a market size of USD 389.5 million in 2023 due to the expansion of the HSV diagnostics market. Covid-19 is the main reason for expansion, where researchers have identified the link between the herpes simplex virus and the SARS-CoV-2 virus in various studies, and a rising number of HSV infections, according to the WHO estimates that 3.7 billion people under 50 have HSV-1, and 491.5 million people aged 15-49 live with HSV-2, indicating a significant and growing population requiring diagnosis,  as people become increasingly informed about the potential consequences of HSV infection, they are more likely to seek testing, driving the herpes simplex virus diagnostics market demand for diagnostics, the development of newer, more accurate HSV tests with improved sensitivity and specificity is facilitating more precise and reliable diagnoses.

Herpes Simplex Virus (HSV) Diagnostics Market Key Developments:
  • In October 2023, Gilead and Assembly Biosciences established a partnership for 12 years to develop next-generation therapeutics for serious viral diseases, with an initial focus on Assembly bio’s established areas of herpes viruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).
  • In October 2021, United BioPharma and the Shanghai Public Health Clinical Centre collaborated with Cheng Kung University in the Department of Microbiology to study the efficacy of UB-621, a best-in-class long-acting medication for genital herpes caused by simplex viruses 1 and 2. (HSV 1 and HSV2).

Herpes Simplex Virus Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.4%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Herpes Simplex Virus (HSV) Diagnostics Market Dynamics

High prevalence of the virus, increasing public awareness, and advancements in rapid testing technology such as nucleic acid amplification tests (NAAT), detect the presence of the viral DNA and are highly sensitive and specific, and most commonly used tests for HSV diagnosis. However, social stigma and inconsistent reimbursement policies pose challenges. The market holds promise in emerging regions such as Asia-Pacific, and Latin America with growing healthcare infrastructure and rising disposable income, and the development of multiplex tests for multiple STIs could further increase accessibility and market growth.

Herpes Simplex Virus Diagnostics Market Segmentation

By Test Type
  • Viral Culture Test
  • Nucleic acid amplification test (NAAT)
  • And Anti-Biotic Test
By Disease Type
  • HSV-I
  • HSV-II
By End User
  • Hospital & Clinics
  • Research Institutions
  • Diagnostic Laboratories

Frequently Asked Questions

The global herpes simplex virus (HSV) diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030, from a market size of USD 389.5 million in 2023.

Abbott Laboratories (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), BD (Becton, Dickinson and Company) (US), Hologic, Inc. (US), Qiagen (Netherlands), Seegene Inc. (South Korea), Agenus Inc. (U.S.), Maruho Co., Ltd. (Japan), Sanofi (France) Norgen Biotek Corp. (Canada), Bio-Rad Laboratories, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Teco Diagnostics (U.S.), and GSK plc. (U.K.)

Asia-Pacific is the fastest growing and North America is the dominant market in HSV diagnostics.

Key Features of the Reports

  • The herpes simplex virus diagnostics market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
  • Merck KGaA (Germany)
  • QIAGEN (Germany)
  • Norgen Biotek Corp. (Canada)
  • Hologic Inc. (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Meridian Bioscience, Inc. (U.S.)
  • Teco Diagnostics (U.S.)
  • GSK plc. (U.K.)
  • Agenus Inc. (U.S.)
  • Maruho Co., Ltd. (Japan)
  • Sanofi (France)
  • Abbott (U.S.)
  • Abcam plc. (U.K.)
  • bioMérieux (France)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • Hoffmann-La Roche Ltd (Switzerland)
  • DiaSorin S.p.A. (Italy)
  • Quidel Corporation (U.S.)
  • Luminex Corporation (U.S.)

Adjacent Markets